Eintrag weiter verarbeiten
Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs?
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Journal of Clinical Oncology, 28, 2010, 15_suppl, S. 2022-2022 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Franceschi, E. Brandes, A. A. Tosoni, A. Bacci, A. Morandi, L. Spagnolli, F. Degli Esposti, R. Bartolini, S. Poggi, R. Ermani, M. Franceschi, E. Brandes, A. A. Tosoni, A. Bacci, A. Morandi, L. Spagnolli, F. Degli Esposti, R. Bartolini, S. Poggi, R. Ermani, M. |
|---|---|
| author |
Franceschi, E. Brandes, A. A. Tosoni, A. Bacci, A. Morandi, L. Spagnolli, F. Degli Esposti, R. Bartolini, S. Poggi, R. Ermani, M. |
| spellingShingle |
Franceschi, E. Brandes, A. A. Tosoni, A. Bacci, A. Morandi, L. Spagnolli, F. Degli Esposti, R. Bartolini, S. Poggi, R. Ermani, M. Journal of Clinical Oncology Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? Cancer Research Oncology |
| author_sort |
franceschi, e. |
| spelling |
Franceschi, E. Brandes, A. A. Tosoni, A. Bacci, A. Morandi, L. Spagnolli, F. Degli Esposti, R. Bartolini, S. Poggi, R. Ermani, M. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2010.28.15_suppl.2022 Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2010.28.15_suppl.2022 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMC4yOC4xNV9zdXBwbC4yMDIy |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMC4yOC4xNV9zdXBwbC4yMDIy |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society of Clinical Oncology (ASCO), 2010 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2010 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
franceschi2010canos6replacepfs6asaprimaryendpointinphaseiistudiesonglioblastomapatientsgivenantiangiogeneticdrugs |
| publishDateSort |
2010 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_unstemmed |
Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_full |
Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_fullStr |
Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_full_unstemmed |
Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_short |
Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_sort |
can os-6 replace pfs-6 as a primary endpoint in phase ii studies on glioblastoma patients given antiangiogenetic drugs? |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2010.28.15_suppl.2022 |
| publishDate |
2010 |
| physical |
2022-2022 |
| description |
|
| container_issue |
15_suppl |
| container_start_page |
2022 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
28 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792328145065476097 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:48:38.034Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Can+OS-6+replace+PFS-6+as+a+primary+endpoint+in+phase+II+studies+on+glioblastoma+patients+given+antiangiogenetic+drugs%3F&rft.date=2010-05-20&genre=article&issn=1527-7755&volume=28&issue=15_suppl&spage=2022&epage=2022&pages=2022-2022&jtitle=Journal+of+Clinical+Oncology&atitle=Can+OS-6+replace+PFS-6+as+a+primary+endpoint+in+phase+II+studies+on+glioblastoma+patients+given+antiangiogenetic+drugs%3F&aulast=Ermani&aufirst=M.&rft_id=info%3Adoi%2F10.1200%2Fjco.2010.28.15_suppl.2022&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792328145065476097 |
| author | Franceschi, E., Brandes, A. A., Tosoni, A., Bacci, A., Morandi, L., Spagnolli, F., Degli Esposti, R., Bartolini, S., Poggi, R., Ermani, M. |
| author_facet | Franceschi, E., Brandes, A. A., Tosoni, A., Bacci, A., Morandi, L., Spagnolli, F., Degli Esposti, R., Bartolini, S., Poggi, R., Ermani, M., Franceschi, E., Brandes, A. A., Tosoni, A., Bacci, A., Morandi, L., Spagnolli, F., Degli Esposti, R., Bartolini, S., Poggi, R., Ermani, M. |
| author_sort | franceschi, e. |
| container_issue | 15_suppl |
| container_start_page | 2022 |
| container_title | Journal of Clinical Oncology |
| container_volume | 28 |
| description | |
| doi_str_mv | 10.1200/jco.2010.28.15_suppl.2022 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMC4yOC4xNV9zdXBwbC4yMDIy |
| imprint | American Society of Clinical Oncology (ASCO), 2010 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2010 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T12:48:38.034Z |
| match_str | franceschi2010canos6replacepfs6asaprimaryendpointinphaseiistudiesonglioblastomapatientsgivenantiangiogeneticdrugs |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 2022-2022 |
| publishDate | 2010 |
| publishDateSort | 2010 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Franceschi, E. Brandes, A. A. Tosoni, A. Bacci, A. Morandi, L. Spagnolli, F. Degli Esposti, R. Bartolini, S. Poggi, R. Ermani, M. 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2010.28.15_suppl.2022 Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? Journal of Clinical Oncology |
| spellingShingle | Franceschi, E., Brandes, A. A., Tosoni, A., Bacci, A., Morandi, L., Spagnolli, F., Degli Esposti, R., Bartolini, S., Poggi, R., Ermani, M., Journal of Clinical Oncology, Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs?, Cancer Research, Oncology |
| title | Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_full | Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_fullStr | Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_full_unstemmed | Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_short | Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| title_sort | can os-6 replace pfs-6 as a primary endpoint in phase ii studies on glioblastoma patients given antiangiogenetic drugs? |
| title_unstemmed | Can OS-6 replace PFS-6 as a primary endpoint in phase II studies on glioblastoma patients given antiangiogenetic drugs? |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2010.28.15_suppl.2022 |